Table 1.
Baseline characteristics of patients.
| Characteristic | Overall |
HRRmt |
HRRwt |
|---|---|---|---|
| n = 43 | n = 26 | n = 17 | |
| Age, year (IQR) | 60 (64-68) | 63 (59-67) | 66 (61-70) |
| Age ≥ 65 yr at baseline, n (%) | 19 (44) | 10 (38) | 9 (53) |
| PSA at baseline, ng/ml (IQR) | 83 (7.7-299.3) | 38 (3.9-276.7) | 100.2 (42.3-466.4) |
| Gleason scorea) | |||
| <8 | 5 (12) | 3 (12) | 2 (12) |
| ≥8 | 34 (79) | 19 (73) | 15 (88) |
| M1 or N1 at diagnosis, n (%) | 35 (81) | 21 (81) | 14 (82) |
| Metastatic site, n (%) | |||
| Viscera: liver or lung | 10 (23) | 4 (15) | 6 (35) |
| Bone, no viscera | 31 (72) | 21 (81) | 10 (60) |
| Lymph node only | 2 (5) | 1 (4) | 1 (6) |
| Metastases volume, n (%) | |||
| High | 36 (84) | 20 (77) | 16 (94) |
| Low | 7 (16) | 6 (23) | 1 (6) |
| Prior new hormonal agent, n (%) | |||
| Enzalutamide only | 0 (0) | 0 (0) | 0 (0) |
| Abiraterone only | 34 (79) | 20 (77) | 14 (82) |
| Enzalutamide and abiraterone | 5 (12) | 3 (12) | 2 (12) |
| Prior docetaxel use, n (%) | 27 (63) | 15 (54) | 13 (76) |
| Prior RP | 13 (30) | 6 (23) | 7 (41) |
| Prior RT | 8 (19) | 7 (27) | 1 (6) |
PSA: prostate-specific antigen; IQR: interquartile range; mCRPC: metastatic castration-resistant prostate cancer; RP: radical prostatectomy; RT: radiation therapy.
a)
Gleason score was not available for four patients.